Division of Critical Care, Department of Anesthesiology, Mayo Clinic, Rochester, MN 55905, USA.
J Intensive Care Med. 2011 Mar-Apr;26(2):59-72. doi: 10.1177/0885066610384195.
Propofol is an alkylphenol derivative named 2, 6, diisopropylphenol and is a potent intravenous short-acting hypnotic agent. It is commonly used as sedation, as well as an anesthetic agent in both pediatric and adult patient populations. There have been numerous case reports describing a constellation of findings including metabolic derangements and organ system failures known collectively as propofol infusion syndrome (PRIS). Although there is a high mortality associated with PRIS, the precise mechanism of action has yet to be determined. The best preventive measure for this syndrome is awareness and avoidance of clinical scenarios associated with development of PRIS. There is no established treatment for PRIS; care is primarily supportive in nature and may include the full array of advanced cardiopulmonary support, including extracorporeal membrane oxygenation (ECMO). This article reviews the reported cases of PRIS and describes the current understanding of the underlying pathophysiology and treatment options.
异丙酚是一种名为 2,6-二异丙基苯酚的烷基酚衍生物，是一种强效的静脉内短效催眠药。它通常被用作镇静剂，也被用作儿科和成人患者的麻醉剂。有许多病例报告描述了一组表现，包括代谢紊乱和器官系统衰竭，统称为异丙酚输注综合征（PRIS）。尽管 PRIS 与高死亡率相关，但确切的作用机制尚未确定。预防这种综合征的最好方法是了解并避免与 PRIS 发展相关的临床情况。目前还没有针对 PRIS 的既定治疗方法；护理主要是支持性的，可能包括全面的高级心肺支持，包括体外膜氧合（ECMO）。本文回顾了 PRIS 的报告病例，并描述了目前对潜在病理生理学和治疗选择的理解。
